Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

We came across a bullish thesis on Boston Scientific Corporation (BSX) on Substack by Magnus Ofstad. In this article, we will ...

Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.

Needham upgraded Boston Scientific Corp (NYSE:BSX) to “Buy”, saying competition from pulsed field ablation (PFA) rivals looks less intense for its key product than it was earlier feared, and citing ...

The stock rose during the quarter after the company reported better-than-expected organic growth and raised its earnings guidance, driven by continued strength in FARAPULSE, its atrial ...

J&J pauses Varipulse pulsed field ablation system's US debut following 4 reports of strokes The Farapulse pulsed field ablation system received its first CE mark in early 2021, shortly before it ...

The Electrophysiology arm continues to gain momentum on the sustained adoption of FARAPULSE PFA. The 2025 guidance indicates strong organic growth over 2024, building confidence in the stock.

The Electrophysiology arm is expected to gain momentum on the sustained adoption of FARAPULSE PFA. The Zacks Consensus Estimate for 2025 EPS has increased over the past 60 days, following 11 ...

The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2025 guidance indicating strong organic growth over 2024 builds confidence in the stock.